Literature DB >> 10694835

The 460Trp polymorphism of the human alpha-adducin gene is not associated with isolated systolic hypertension in elderly Australian Caucasians.

S Alam1, N Liyou, D Davis, M Tresillian, A G Johnson.   

Abstract

The study was undertaken to determine whether polymorphic variants of the alpha-adducin gene are associated with isolated systolic hypertension (ISH) in elderly Australian Caucasians. Participants were classified with ISH (n = 87, systolic blood pressure (SBP) > or =160 mm Hg and diastolic blood pressure (DBP) < or =90 mm Hg) or normotension (n = 124, SBP <140 mm Hg and DBP <90 mm Hg with no family history of hypertension). To collect demographic data, a structured questionnaire was used. DNA was extracted using standard techniques from 211 subjects (age range 61-89, mean age 73 +/- 6.6 years, male: female ratio 1.1:1). Genotypes (gly/gly, trp/gly and trp/trp) were assigned in triplicate by polymerase chain reaction (PCR) followed by electrophoresis, using a laser scanning electrophoresis unit. The validity of the method was confirmed by sequencing. Frequencies of allele distribution in ISH or control groups were determined by Chi-square tests and a stepwise logistic regression model, which controlled for potential confounders, was used to examine any independent association between alpha-adducin genotypes or alleles with ISH and normotensive controls. Mean BP (+/- s.d.) was: 170/79.8 +/- 14.9/8.3 mm Hg and 122.1/ 73.4 +/- 8. 8/7.6 mm Hg in the ISH and normotension groups respectively. The unadjusted allele and genotypes frequencies were not significantly different in the ISH patients groups compared with normotensive controls (chi2 = 1.59, P = 0.45 and chi2 = 1.23, P = 0.28 respectively). In this elderly cohort, after adjustment for potential confounders, no statistically significant association was found between alpha-adducin genotype and SBP (P = 0.65 for homozygotes, P = 0.59, for heterozygotes), DBP (P = 0.49 homozygotes, for heterozygotes P = 0.45) pulse pressure (P = 0.87 homozygotes, for heterozygotes P = 0.95) diagnosis of ISH (P = 0.72 for homozygotes, P = 0.68 for heterozygotes). However age and renal disease predicted the diagnosis of ISH (P = 0.001, P = 0.459, respectively), a large pulse pressure (P < 0.0001, P = 0.033, respectively) and a higher SBP (P < 0.0001, P = 0.025, respectively) in this large cohort of elderly Australian Caucasian volunteers. Journal of Human Hypertension (2000) 14, 199-203.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10694835     DOI: 10.1038/sj.jhh.1000944

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  5 in total

Review 1.  The adducin saga: pleiotropic genomic targets for precision medicine in human hypertension-vascular, renal, and cognitive diseases.

Authors:  Ezekiel Gonzalez-Fernandez; Letao Fan; Shaoxun Wang; Yedan Liu; Wenjun Gao; Kirby N Thomas; Fan Fan; Richard J Roman
Journal:  Physiol Genomics       Date:  2021-12-03       Impact factor: 3.107

2.  Alpha-adducin Gly460Trp polymorphism and hypertension risk: a meta-analysis of 22 studies including 14303 cases and 15961 controls.

Authors:  Kuo Liu; Jielin Liu; Yan Huang; Ya Liu; Yuqing Lou; Zuoguang Wang; Hong Zhang; Shan Yan; Zhizhong Li; Shaojun Wen
Journal:  PLoS One       Date:  2010-09-28       Impact factor: 3.240

3.  Gly460Trp polymorphism of the ADD1 gene and essential hypertension in an Indian population: A meta-analysis on hypertension risk.

Authors:  P Ramu; G Umamaheswaran; D G Shewade; R P Swaminathan; J Balachander; C Adithan
Journal:  Indian J Hum Genet       Date:  2010-01

4.  Association of alpha-ADD1 Gene and Hypertension Risk: A Meta-Analysis.

Authors:  Xiaoyang Liao; Weiwen Wang; Zhi Zeng; Zhiyi Yang; Hua Dai; Yi Lei
Journal:  Med Sci Monit       Date:  2015-06-04

Review 5.  A Review on Adducin from Functional to Pathological Mechanisms: Future Direction in Cancer.

Authors:  Karrie Mei-Yee Kiang; Gilberto Ka-Kit Leung
Journal:  Biomed Res Int       Date:  2018-05-16       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.